HIV Medicine

Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents
pp. 263-268(6)
Authors: Dollfus, C; Blanche, S; Trocme, N; Funck-Brentano, I; Bonnet, F; Levan, P

Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort
pp. 269-273(5)
Authors: Alvarez-Uria, G; Ratcliffe, L; Vilar, JF

Mortality is influenced by locality in a major HIV/AIDS epidemic
pp. 274-281(8)
Authors: Druyts, EF; Rachlis, BS; Lima, VD; Harvard, SS; Zhang, W; Brandson, EK; Strathdee, SA; Montaner, JSG; Hogg, RS

Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19)
pp. 282-289(8)
Authors: Rosenthal, E; Salmon-Céron, D; Lewden, C; Bouteloup, V; Pialoux, G; Bonnet, F; Karmochkine, M; May, T; François, M; Burty, C; Jougla, E; Costagliola, D; Morlat, P; Chêne, G; Cacoub, P

Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution
pp. 290-301(12)
Authors: Williams, PL; Wu, JW; Cohn, SE; Koletar, SL; McCutchan, JA; Murphy, RL; Currier, JS

Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study
pp. 302-309(8)
Authors: Lo, Y-C; Chen, M-Y; Sheng, W-H; Hsieh, S-M; Sun, H-Y; Liu, W-C; Wu, P-Y; Wu, C-H; Hung, C-C; Chang, S-C

Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
pp. 310-317(8)
Authors: Mahungu, TW; Smith, CJ; Turner, F; Egan, D; Youle, M; Johnson, MA; Khoo, S; Back, DJ; Owen, A

Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers
pp. 318-327(10)
Authors: Tomaka, F; Lefebvre, E; Sekar, V; Van Baelen, B; Vangeneugden, T; Vandevoorde, A; Diego Miralles, G